Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06212466 · ClinicalTrials.gov registry record
MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)
A clinical trial, sponsored by Genetesis.
- Completed
- Registry status
- 136
- Enrollment target
NCT06212466: Completed study, sponsored by Genetesis.
NCT06212466 is a clinical trial that has completed, run by Genetesis. The registered enrollment target is 136 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06212466 has completed, sponsored by Genetesis.
- COMPLETED
- Registry status
- 136 participants
- Enrollment target
Study Summary
A prospective, multicenter, observational, single-arm trial to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction in patients with suspected ischemia and confirmed no obstructive coronary artery disease (suspected INOCA) by using diagnostic measures of coronary flow reserve (CFR) via invasive angiography as a reference standard for diagnosis.
Primary Outcome
Diagnostic accuracy of CardioFlux MCG in determining the presence of coronary microvascular dysfunction, as measured by AUC with ground truth defined as an invasive CFR \<2.5 for bolus thermodilution method. H0: AUC\<0.55 Ha: AUC≥0.55
Interventions
- DEVICE CardioFlux
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2024-06-03 |
| Est. Completion | 2025-04-15 |
What the finished NCT06212466 record still lists
NCT06212466 is an observational study that tracks outcomes without assigning an intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which CardioFlux is the first listed.
NCT06212466 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06212466 about?
NCT06212466 is a clinical study titled "MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)". A prospective, multicenter, observational, single-arm trial to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction in patients with suspected ischemia and confirmed no obstructive coronary artery disease (suspected INOCA) by using diagnostic...
What is the current status of trial NCT06212466?
This trial is currently completed. The enrollment target is 136 participants. The study started on 2024-06-03. Estimated completion is 2025-04-15.
What interventions are being tested in trial NCT06212466?
The interventions under investigation include: CardioFlux (DEVICE).
Who is sponsoring clinical trial NCT06212466?
This trial is sponsored by Genetesis, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI